Sequential treatment of tyrosine kinase inhibitor and platinum-based doublet chemotherapy on EGFR mutant non-small cell lung cancer: a meta-analysis of randomized controlled clinical trials

References

• ChenWZhengRBaadePDCancer statistics in China, 2015CA Cancer J Clin201666211513226808342
   PubMed Web of Science ®Google Scholar
• EttingerDSWoodDEAkerleyWNon-small cell lung cancer, version 6. 2015J Natl Compr Canc Netw201513551552425964637
   PubMed Web of Science ®Google Scholar
• ShiYZhangLLiuXIcotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trialLancet Oncol2013141095396123948351
   PubMed Web of Science ®Google Scholar
• RosellRMoranTQueraltCScreening for epidermal growth factor receptor mutations in lung cancerN Engl J Med20093611095896719692684
   PubMed Web of Science ®Google Scholar
• FukuokaMWuYLThongprasertSBiomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)J Clin Oncol201129212866287421670455
   PubMed Web of Science ®Google Scholar
• GridelliCCiardielloFGalloCFirst-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trialJ Clin Oncol201230243002301122778317
   PubMed Web of Science ®Google Scholar
• WuYLZhouCLiamCKFirst-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE studyAnn Oncol20152691883188926105600
   PubMed Web of Science ®Google Scholar
• MitsudomiTMoritaSYatabeYGefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialLancet Oncol201011212112820022809
   PubMed Web of Science ®Google Scholar
• WuYLZhouCHuCPAfatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trialLancet Oncol201415221322224439929
   PubMed Web of Science ®Google Scholar
• SequistLVYangJCYamamotoNPhase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutationsJ Clin Oncol201331273327333423816960
   PubMed Web of Science ®Google Scholar
• YangJCWuYLSchulerMAfatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trialsLancet Oncol201516214115125589191
   PubMed Web of Science ®Google Scholar
• RosellRCarcerenyEGervaisRErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialLancet Oncol201213323924622285168
   PubMed Web of Science ®Google Scholar
• InoueAKobayashiKMaemondoMUpdated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemonaive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)Ann Oncol2013241545922967997
   PubMed Web of Science ®Google Scholar
• ZhouCWuYLChenGFinal overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)Ann Oncol20152691877188326141208
   PubMed Web of Science ®Google Scholar
• ZhangYSunYWangLSequential treatment of tyrosine kinase inhibitors and chemotherapy for EGFR-mutated non-small cell lung cancer: a meta-analysis of Phase III trialsOnco Targets Ther201361771177724348052
   PubMed Web of Science ®Google Scholar
• MitsudomiTMoritaSYatabeYUpdated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR)J Clin Oncol201230suppl abstr 7521
   Google Scholar
• LeonLFGolsorkhiALiuSDrozdowskyjARosellROverall survival analyses of first-line erlotinib versus chemotherapy in the EURTAC study population controlling for the use of post-study therapyAnn Oncol201425suppl 4iv426iv470
   Google Scholar
• MiyauchiEInoueAKobayashiKEfficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002)Jpn J Clin Oncol201545767067625877748
   PubMedGoogle Scholar
• YuHAArcilaMERekhtmanNAnalysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancersClin Cancer Res20131982240224723470965
   PubMed Web of Science ®Google Scholar
• JännePAYangJCKimDWAZD9291 in EGFR inhibitor-resistant non-small-cell lung cancerN Eng J Med20153721816891699
   PubMed Web of Science ®Google Scholar
• WangSTsuiSTLiuCSongYLiuDEGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancerJ Hematol Oncol2016915927448564
   PubMed Web of Science ®Google Scholar
• SoriaJCWuYLNakagawaKGefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trialLancet Oncol201516899099826159065
   PubMed Web of Science ®Google Scholar
• Paz-AresLde MarinisFDediuMMaintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trialLancet Oncol201213324725522341744
   PubMed Web of Science ®Google Scholar
• YangCJTsaiMJHungJYPemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based chemotherapy after developing resistance to the first-line gefitinib treatmentOnco Targets Ther201691579158727051298
   PubMed Web of Science ®Google Scholar
• KiuraKChemotherapy for lung cancer: still alive!Jpn J Clin Oncol201545760961025989990
   PubMedGoogle Scholar